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Abstract
Invasive melanoma is the most lethal form of skin cancer. The treatment of melanoma-derived cell lines with 5-aza-29-
deoxycytidine (5-Aza-dC) markedly increases the expression of several miRNAs, suggesting that the miRNA-encoding genes
might be epigenetically regulated, either directly or indirectly, by DNA methylation. We have identified a group of
epigenetically regulated miRNA genes in melanoma cells, and have confirmed that the upstream CpG island sequences of
several such miRNA genes are hypermethylated in cell lines derived from different stages of melanoma, but not in
melanocytes and keratinocytes. We used direct DNA bisulfite and immunoprecipitated DNA (Methyl-DIP) to identify
changes in CpG island methylation in distinct melanoma patient samples classified as primary in situ, regional metastatic,
and distant metastatic. Two melanoma cell lines (WM1552C and A375 derived from stage 3 and stage 4 human melanoma,
respectively) were engineered to ectopically express one of the epigenetically modified miRNA: miR-34b. Expression of miR-
34b reduced cell invasion and motility rates of both WM1552C and A375, suggesting that the enhanced cell invasiveness
and motility observed in metastatic melanoma cells may be related to their reduced expression of miR-34b. Total RNA
isolated from control or miR-34b-expressing WM1552C cells was subjected to deep sequencing to identify gene networks
around miR-34b. We identified network modules that are potentially regulated by miR-34b, and which suggest a
mechanism for the role of miR-34b in regulating normal cell motility and cytokinesis.
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Introduction
Melanoma, a cancer of pigment producing cells in the skin, has
complex origins influenced by genetic predisposition, prolonged
exposure to ultraviolet rays of the sun, and the extent of melanin
pigmentation of the skin. As in most cancers, melanomas often have
epigenetic changes in regulatory genes, such as CpG methylation in
59-upstream cis regulatory elements, and chromatin protein
modification signatures [1,2,3]. The recent discovery of miRNAs
and their epigenetic regulation adds further complexity as they have
been shown to be important influences on posttranscriptional gene
regulation in cancer cells [4]. Since miRNA precursor genes are
usuallynested withinotherprotein codinggenes,often withinintron
sequences, misregulation of these protein-coding genes by epige-
neticmechanismsmayalso beexpected tocauseaberrantregulation
of the miRNA target genes. miRNA gene silencing by CpG island
methylation has been reported in several cancers [5,6,7], though
little is known in this regard for melanomas [8].
It has recently been reported that a number of miRNAs are
differentially regulated in melanoma, several of which appear to
regulate melanoma cell invasiveness [9,10,11,12,13,14]. The miR-
NAs miR-221 and miR-222 down-regulate p27Kip1/CDKN1B and
the c-KIT receptor mRNA levels, which leads to progression of
neoplasia through enhanced proliferation and reduced differentiation
of melanoma cells [15]. Another miRNA, miR-137, down-regulates
the expression of MITF, a master regulator of cell growth,
maturation, and pigmentation in melanoma cells [16]. We and
others have shown that several miRNA genes are differentially
r e g u l a t e di nm e l a n o m ac e l l s ,a n do n es u c hm i R N A ,m i R - 2 1 1 ,i s
consistently reduced in melanoma but not in melanocytes [17,18].
The epigenetic silencing of miR-375 has also been recently shown by
us in melanoma [19], suggesting a mechanism for regulation of
cellular morphology and tissue networking.
miR-34b was previously reported to be epigenetically regulated
in several cancers, including melanoma, colorectal, and head and
neck cancer [8], and reduces the oncogenic potential of a head
and neck cancer-derived cell line [8]. The fact that epigenetic
silencing of miR-34b was shown in all three cancers but played
an inhibitory role in oncogenesis for only one suggests that this
miRNA may play distinct roles in unrelated cancers. To our
knowledge, the functional significance of miR-34b in normal
melanocytes and melanoma cells has not yet been investigated.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24922Here, we report that cell lines derived from malignant
melanomas and melanoma patient samples have hypermethy-
lated CpG islands in the 59-upstream regions of several miRNA-
coding genes, including that of miR-34b. We engineered two cell
lines derived from metastatic melanoma to ectopically express
miR-34b, and show that these cells exhibit reduced cell motility,
decreased substrate attachment, and reduced invasion. Next-
generation sequencing revealed additional potential target genes
that are modulated by the ectopic expression of miR-34b in
melanoma cells, and many are predicted to function in a network
of interacting products enriched for cytoskeletal proteins.
Collectively, these results suggest that epigenetic silencing of
miR-34b may be responsible for some important oncogenic
characteristics of melanoma cells, including cell motility and
migration.
Results
Identification of epigenetically regulated miRNAs in
melanoma cell lines
The reduced expression of genes that are under the control of
CpG island methylation is often reversed by treating the cells
with the DNA methyl transferase inhibitor 5-Aza-29-deoxycyti-
dine (5-Aza-dC). To assess the range and extent of miRNA
expression under direct or indirect control of DNA methylation,
we treated the melanoma cell line WM1552C (derived from a
stage 3 malignant melanoma) with 5-Aza-dC and measured
changes in miRNA gene expression using miRNA microarrays
(see Methods). Several miRNAs, including miR-34b, -489, -375, -
132, -142-3p, -200a, -145, -452, -21, -34c, -496, -let7e, -654, and
-519b, were found to be up-regulated in WM1552C cells treated
with 5-Aza-dC relative to untreated cells (Figure 1). Three
miRNA genes (mir-34b, -34c, -375) whose products exhibited
modulated expression in response to 5-Aza-dC treatment are
known to contain CpG islands in their putative regulatory regions
[20,21]. Of these, mir-34b was found to be the most responsive to
5-Aza-dC treatment.
CpG island methylation at the 59 upstream region of miR-
34b in melanoma
miR-34b has a distinct CpG island located between –631 and –
395 bp upstream of its precursor RNA start site, which contains 22
CpG dinucleotides. To examine the methylation patterns within
the CpG islands, the genomic DNA of melanocytes and
WM1552C cells was purified, bisulfite-treated, and sequenced.
The sequence data were then compared to that of untreated
genomic DNA isolated from the same cells. Negligible CpG
methylation was observed in normal melanocyte and keratinocyte
cell lines, and in melanoma cell lines obtained from stage 1
(WM793B) and stage 2 (WM278) melanoma tumors. However,
this region was found to be highly methylated in cell lines obtained
from stage 3 (WM1552C) and stage 4 (A375) melanoma tumors
(Figure 2A). Treatment of WM1552C with 10 mM 5-Aza-dC
largely erased CpG methylation at these sites (Figure 2B). miR-34b
expression was increased in a dose-dependent manner by treating
WM1552C cells with 5-Aza-dC, with maximum induction
observed at 10 mM 5-Aza-dC (Figure 2C), the same concentration
that reversed most of the upstream CpG methylation (Figure 2B).
These results were confirmed in a parallel series of independent
experiments in which methylated genomic DNA was first enriched
by binding to reagents having high affinity to methylated DNA
(see Methods), followed by next-generation DNA sequencing
(Figure 2D).
miR-34b CpG island methylation in melanoma patients
and normal skin
Given the strong hypermethylation profile observed in the
upstream sequences of miR-34b in late-stage melanoma cell lines,
we next examined methylation levels in biopsied samples from
patients with late-stage (Stage 3 and 4) melanoma. Bisulfite
conversion and sequencing of DNA from normal skin and nevi
samples revealed that the 59 upstream sequences of miR-34b were
largely hypomethylated (Figure 3), except at two sites located near
the 59 end (sites #2 and #3). This hypermethylation was also
observed in keratinocytes (Figure 2A), suggesting that CpG
methylation at these two sites may not be melanoma-specific.
We next examined CpG island methylation of miR-34b in 24
melanoma patient samples separated into four groups: (a) primary
melanoma, (b) regional metastases, (c) distant metastases, and (d)
nodal metastases. Three of six primary, four of six regional
metastases, and two of six distant metastases melanoma samples
were found to be hypermethylated (Figure 3). Interestingly, none
of the nodal metastases showed significant methylation in this
region.
The miR-34b methylation in melanoma patients indicates that
methylation of this CpG island is detectable from patient samples,
and may therefore hold the possibility of serving as a putative
biomarker for stage 3 and 4 melanomas. However, there were only
24 patient samples of four groups of melanoma (primary, regional,
distant and nodal). Thus, due to small sample size it is not possible
to make an accurate statistical conclusion. Currently, we are
continuing this study with a larger patient population with our
collaborators (clinical partners). miR-34b expression in patient
samples were tested by qRT-PCR and the results are shown as
Figure S1.
Figure 1. Activation of miRNA expression in response to 5-Aza-
dC. Hierarchical clustering of differentially expressed miRNAs in
melanoma cells after 5-Aza-dC treatment. 5-Aza-dC-induced expression
changes ranged from highly upregulated (bright red) to marginally
upregulated (dark red); black represents no change.
doi:10.1371/journal.pone.0024922.g001
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modulates both coding and non-coding RNA genes
To understand the significance of miR-34b in malignant
melanoma, we stably expressed the mir-34b gene in the stage 3
melanoma cell line WM1552C, and analyzed genome-wide gene
expression patterns in the engineered cells (WM1552C/34b) by
deep sequencing (Figure S2). Total RNA was isolated from
WM1552C/34b cells or cells expressing the vector only
(WM1552C/VO) and the relative abundances of coding and
non-coding RNAs were analyzed. Sequence reads were mapped to
the latest version of the human genome sequence (hg19) using two
mapping algorithms (see Methods).
The most differentially expressed genes were enriched for Gene
Ontology categories of ‘‘cytoskeletal remodeling’’ (both TGF- and
WNT-dependent and independent) and ‘‘cell adhesion’’ pathway
network modules (Figure S3A), suggesting a direct or indirect
mechanistic link between miR-34b expression and expression of
genes related to cytoskeletal remodeling. Figure S3B and Table S1
show the most differentially expressed mRNAs, of which 34 were
down-regulated and 19 up-regulated. Most of these genes are
involved in regulating cell morphology, cell movement, and cell
growth, and many of them (ALCAM, CAV1, DKK1, INHBA,
MIA, MMP8, S100B, STC1, TGFBI, THBS2, TNS3, and
WNT5A) have also been implicated in cell proliferation, migration,
cell adhesion, invasion, and metastasis [22,23,24,25,26]. Interest-
ingly, ALCAM, CAV1, DKK1, MIA, MMP8, S100B, and
WNT5A have previously been shown to be involved in melanoma
progression [27,28,29,30,31,32,33], and MIA and S100B are
utilized clinically as biomarkers for melanoma [31,32]. It is worth
noting that CAV1, found to be down-regulated in WM1552C/34b
cells, was previously identified as a target for miR-34b [34].
Next, we directed our attention to two of the differentially
e x p r e s s e dm R N A s( T H B S 2a n dD K K 1 )a n dv a l i d a t e dt h e i r
expression by Taqman qRT-PCR analysis (Figure S3C). THBS2,
whose expression is up-regulated by ectopically expressed miR-34b,
was chosen because it has previously been suggested to modulate cell
adhesion and migration [35] and because it can act as a potent
endogenous inhibitor oftumor growth and angiogenesis[36]. DKK1,
whose expression is down-regulated by miR-34b, was chosen because
its expression is also up-regulated in many cancers including
myelomas, hepatocellular carcinomas, and breast and colorectal
cancers [37,38]. Additionally, high DKK1 expression correlates with
poor prognosis in hepatocellular carcinoma [39]. qRT-PCR analysis
revealed that THBS2 expression was 2.5-fold higher in WM1552C/
34b cells than in WM1552C/VO cells, whereas DKK1 was nearly
10-fold lower in WM1552C/34b (Figure S3).
Next-generation RNA sequencing also revealed a number of
miRNAs that were differentially expressed in response to miR-34b
Figure 2. mir-34b 59-UPS CpG island methylation in melanocytes, keratinocytes, and melanoma cells, and the effect of 5-Aza-dC
demethylation on its expression in melanoma cells. A) Frequency of CpG island methylation in the mir-34b 59-UPS measured by bisulfite
genomic sequencing (horizontal line at top; numbers represent nucleotides relative to the transcription start site, and vertical lines represent the
positions of CpG islands). Nine clones from each cell line were tested. Black boxes represent methylated sites, white boxes represent no methylation.
WM793B=Stage 1, WM278=Stage 2, WM1552C=Stage 3, A375=Stage 4. B) WM1552C cells were treated with 5-Aza-dC and the putative mir-34b
promoter in nine clones was then examined for CpG island methylation (conventions as described in A). C) Northern blot analysis of miR-34b
expression in WM1552C cells after treatment with various concentrations of 5-Aza-dC. U6 RNA was used as a loading control. D) Methyl-DIP deep
sequencing of the upstream CpG island sequences of mir-34b in melanocytes, WM1552C, and 5-Aza-dC treated WM1552C cells. Y-axes depict RPKM
values and the horizontal green bar indicates the CpG island. The histograms represent the extent of CpG methylation.
doi:10.1371/journal.pone.0024922.g002
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(miR-20b, -134, -140, and -199b) are reportedly involved in cancer
progression [40,41,42,43]. In support of these findings, qRT-PCR
analysis of miR-140 showed nearly 3-fold higher levels in
WM1552C/34b cells than in WM1552C/VO cells (Figure S4B).
Deep sequencing revealed that mRNA expression of a group of
19 computationally predicted target genes were down-regulated in
WM1552C/34b cells (Figure 4A). Of these putative targets, 15 are
known to be involved in cytoskeletal rearrangement, cell
morphology, cell adhesion, cell motility, and invasion (Figure 4B).
Four of these 15 genes (CAPZA1, CDC42, NCKAP1, and
PPP1CB) were previously shown to regulate actin filament
polymerization and/or reorganization [44,45,46,47]. We con-
firmed by qRT-PCR analysis that two of these genes (CDC42 and
FN1) were down-regulated in WM1552C/34b cells compared
with control cells (Figure 4C): CDC42 expression was 90% lower
and FN1 expression was nearly 70% lower. Taken together, these
data suggest that miR-34b regulates genes associated with
cytoskeletal remodeling, migration, and invasion.
The effect of miR-34b on melanoma cell growth,
adhesion, migration, and invasion
Since miR-34b expression appears to be epigenetically regulat-
ed in late-stage melanomas, we examined its effects on the
functional phenotype of melanoma cells using various cell biology
assays. WM1552C/34b cells showed decreased cell adhesion
compared to WM1552C/VO cells, which was apparent within
15 minutes of plating and became more pronounced over the
Figure 3. CpG islands 59UPS of mir-34b are hypermethylated in clinical melanoma samples. CpG island methylation in the putative mir-
34b promoter was measured by bisulfite genomic sequencing (conventions are as appeared in Figure 2). Six clones from each sample were tested.
Patient samples are annotated as follows: (P)=primary melanoma, (R)=regional metastasis, (D)=distant metastasis, (N)=nodal metastasis.
doi:10.1371/journal.pone.0024922.g003
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miR-34b in A375 cell line decreased cell adhesion significantly
compared with vector-transfected cells within 30 minutes of
plating (Figure 5B).
We next examined the effect of miR-34b on the invasive
properties of miR-34b-expressing cells. WM1552C/34b and
A375/34b cells, as well as vector only and untransfected control
cells, were seeded into invasion chambers and allowed to migrate
for 48 hrs. There was a significant reduction (46%) in migration of
WM1552C/34b cells compared with either WM1552C or
WM1552C/VO cells (Figure 5C and 5D). A375/34b cells showed
a similar trend (52%), reduction of cell migration compared to
A375 or A375/VO cells (Figure 5E and 5F).
Finally, we performed a wound-healing assay to assess the effect
of miR-34b on cell motility. A striking difference was observed in
the rates of motility of WM1552C/34b cells compared to control
cells as early as 4 hrs after the initial scratch (Figure 6A and 6C).
By 8 hrs, the WM1552C/34b-expressing cells had migrated less
than half of the distance of WM1552C/VO cells, and full wound
closure required 24 hrs for WM1552C/34b, compared with only
16 hrs for control cells. A less pronounced effect was seen in
A375/34b cells, which closed the scratch within 24 hrs compared
to 20 hrs for A375/VO cells (Figure 6B and 6D). Taken together,
these results highlight the importance of miR-34b regulation for
cell adhesion, invasion, and motility in human melanomas.
Discussion
We have identified a group of epigenetically regulated miRNA
genes in melanoma cells, including miR-34b, -489, -375, -132, -
142-3p, -200a, -145, -452, -21, -34c, -496, -let7e, -654, and -519b.
We used direct DNA bisulfite and immunoprecipitated methylated
DNA (methyl-DIP) deep sequencing to confirm that the upstream
CpG island sequences of one such miRNA gene (miR-34b) are
hypermethylated in advance melanomas. By contrast, CpG
methylation of miR-34b was less extensive in stage 1 and 2
melanoma samples, normal melanocytes, and keratinocytes.
Abnormalities in CpG island methylation were also seen in
melanoma patient samples classified as primary in situ, regional
metastatic, and distant metastatic tumors. Interestingly, no miR-
34b methylation was detected in nodal metastatic samples, but the
significance of this observation remains unclear. It is possible that
the panel of nodal metastatic melanoma samples (n=6) was not
large enough to detect hypermethylation. Alternatively, nodal
metastatic melanoma cells might be epigenetically distinct from
distant metastatic melanoma cells. Further studies are needed to
resolve this issue.
Ectopic expression of miR-34b in the stage 3 and stage 4
melanoma cell lines caused a reduction in cell invasion, motility,
and attachment rates, suggesting that the invasiveness of the
WM1552C and A375 parental cell lines may be related to their
low expression of miR-34b. RNA samples isolated from miR-34b-
transfected and nontransfected WM1552C cells were subjected to
deep sequencing to identify gene networks around miR-34b.
These results identified network modules related to cytoskeletal
remodeling and cell invasion, suggesting a mechanism by which
miR-34b might regulate normal cell motility and cytokinesis.
These observations are consistent with the existence of a global
network of miRNAs and coding genes that is perturbed by miR-
34b in melanoma cells; future analysis of this network may provide
candidates for melanoma biomarkers.
Several groups have previously reported the importance of miR-
34b in human melanomas [48,49,50,51,52,53,54]. Lujambio et al.
[8], showed that the miR-34b upstream DNA sequences are
hypermethylated in melanoma patient samples. Our results are
consistent with this observation for advanced melanoma patient
samples. Methylation-associated silencing of miR-127 and miR-
124a in T24 and HCT-116 cancer cell lines has been reported
[6,7]. Recently, epigenetic silencing of miR-375 was reported in
melanoma cell lines and patient samples [19]. Interestingly, all
three miR-34 members (a, b, and c) are reported to be methylated
and silenced to varying degrees in many cancers [34,53,55]. Our
methyl-DIP deep-sequencing results confirmed that the upstream
CpG island sequences of miR-34b and miR-34c are highly
hypermethylated in melanoma.
During melanoma formation, the initial genetic or epigenetic
changes are thought to precede additional mutations and further
epigenetic changes that affect the function of several signaling
pathways. Aberrant DNA methylation patterns at the 59
noncoding region of the INK4a gene was discovered in melanoma
[56], which is consistent with the involvement of epigenetic factors
in melanoma development or progression. Similarly, epigenetic
silencing of PTEN expression occurs in certain malignant
melanomas with no detectable mutation in the PTEN gene [57].
While the impact on melanoma development of epigenetic
changes in several protein-coding genes is appreciated, there have
been few reports of the impact of epigenetic regulation of non-
coding RNAs, such as miRNAs.
The epigenetic modification of miR-34b may serve as a useful
biomarker for early melanoma detection in humans, and
therefore, one could propose to develop a novel sensitive miR-
34b epigenetic biomarker assay to screen skin biopsies in
melanoma patients. Including a panel of non-coding RNA
epigenetic markers in to widely used pathological and genetic
markers will be advantageous for both patients and pathologists.
An investigation of miR-34b regulation and associated CpG island
methylation in a large group of melanoma patient samples, in
comparison with samples of matched normal tissues or melano-
cytic nevi, is both relevant and timely. Mir-34 group of miRNAs
are known to be useful therapeutic target for various cancers [58],
and MIRNATherapeutics Inc., (http://www.mirarx.com), a
biopharmaceutical research company is currently focusing on
miR-34 group of genes as therapeutics.
In this study, we have identified many miRNA genes that are
perturbed by treatment with a DNA methylation inhibitor, and
have used deep sequencing to document a large collection of
coding and non-coding RNA genes perturbed by the ectopic
expression of miR-34b in melanoma cell lines. Thus, this
report will also serve as a resource for future studies on the role
of epigenetic regulation of non-coding RNAs in melanoma
cells.
Figure 4. Differential expression of putative miR-34b target genes in miR-34b–expressing melanoma cells. A) A heat-map of the top
potential miR-34b targets suggested by TargetScan 5.1, based on fold change and transcript differences between WM1552C/34b cells vs. WM1552C/
VO cells. Green boxes indicate gene targets associated with the network of cytoskeletal rearrangement shown in (B). B) Pathway mapping of the top
potential miR-34b targets reveals 15 targets all associated with the network of cytoskeletal rearrangement. Targets are indicated in green. C) qRT-PCR
validation of the differential expression of putative miR-34b targets CDC42 and FN1 in vector-transfected or miR-34b-transfected WM1552C cells.
Values are listed as relative quantities (RQ).
doi:10.1371/journal.pone.0024922.g004
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24922Figure 5. Effect of miR-34b on melanoma cell attachment and invasion. A) and B) Cell adhesion assays comparing WM1552C/VO and
WM1552C/34b cells (A), or A375/VO and A375/34b cells (B). Data are percent of input cells bound, mean 6 (SEM) of triplicates. C) and D) Cell invasion
assays comparing untransfected WM1552C cells to stable WM1552C/VO and WM1552C/34b cells. E) and F) Cell invasion assays comparing
untransfected A375 cells to stable A375/VO and A375/34b cells. All assays were performed in triplicate. Asterisks indicate statistical significance by
Kruskal Wallis nonparametric test, P,0.005.
doi:10.1371/journal.pone.0024922.g005
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Cell lines and clinical samples
Experimental studies described in this manuscript used the human
epidermal melanocyte cell line HEM-l (ScienCell, Catalog # 2200,
grown in MelM media containing MelGS growth supplements, 0.5%
fetal bovine serum (FBS), penicillin and streptomycin), human
epidermal keratinocytes (HEK, ScienCell, Catalog # 2100, grown in
Keratinocyte Medium, ScienCell, Catalog # 2101), and the
melanoma cell lines WM793B (stage 1, Wistar Institute), WM278
(stage 2, Wistar Institute), WM1552C (stage 3, American Type
Culture Collection Number: CRL-2808), and A375 (stage 4,
American Type Culture Collection). Melanoma cells were grown
in Complete Tu Medium containing a 4:1 mixture of MCDB-153
medium with 1.5 g/L sodium bicarbonate and Leibovitz’s L-15
medium with 2 mM L-glutamine, 2% FBS, and 1.68 mM CaCl2.
All clinical samples were graciously donated by Dr. James
Goydos, Robert Wood Johnson Medical School.
Isolation and bisulfite treatment of genomic DNA
Genomic DNA prepared from 10
7 of each cell line. Cells were
harvested by trypsinization, washed once in phosphate-buffered
saline (PBS), and purified using the QiaAmp DNA mini kit
(QIAGEN). DNA from 25 mg of patient samples was isolated by
overnight incubation with proteinase K at 55uC, with subsequent
purificationusingtheQiaAmpDNAminikit(QIAGEN).Allsamples
were quantified using the ND-1000 spectrophotometer (Nanodrop).
DNA (0.5 mg) was treated with sodium bisulfite using the EZ DNA
methylation kit (Zymo Research) and eluted in 10 mL elution buffer.
Sequencing of PCR products from bisulfite-converted
genomic DNA for detection of CpG island methylation
Bisulfite-treated genomic eluate (2 mL) was used for bisulfite
PCR using the following primer combinations: let7i f1
(GGGGGTAGTTTAGAATTAGTTGGTGTTTG) and let7i r1
(CCCCTTCTTTTCCTTTACCTTCCC) to produce a 301-bp
product, 124a No-C-For (GGAAAGGGGAGAAGTGTGGG)
and 124-3 Rev (CACCGCGTACCTTAATTATATAAAC) to
produce a 260-bp product, & miR34b f1 (GAATTTGGGTTTT-
TATTTTTTAGG) and miR34b r1 (CCAAACCCTAAAAC-
TAACTCTCTC) to produce a 236-bp product. PCR was
performed using a 6-min hot start at 95uC, followed by 35 cycles
at 94uC for 20 s, 54uC for 25 s, and 72uC for 30 s, ending with a
10-min extension at 72uC using AmpliTaq Gold (Applied
Figure 6. Effect of miR-34b on cell migration. Wound healing assay for melanoma cells. A) and B) Representative images of WM1552C/VO and
WM1552C/34b cells or A375/VO and A375/34b cells. Images were taken between 0 and 20 hrs after scratch formation. C) and D) Quantitation of
experiments shown in (A) and (B), performed in triplicate. The percent surface area between the wounds was calculated using NIS elements software.
Each time point was compared with the 0 hr time point of the respective cell line. Asterisks indicate statistical significance by Kruskal Wallis
nonparametric test, P,0.005.
doi:10.1371/journal.pone.0024922.g006
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using the QiaQuick gel extraction kit (QIAGEN) and cloned into
the pCR4-TOPO vector (Invitrogen/Life Technologies). Nine
clones for each miRNA candidate and 6 clones for each patient
sample were sequenced using M13 primers and the BigDye
terminator kit v1.1 (Applied Biosystems/Life Technologies),
analyzed on a 31306l Genetic Analyzer (Applied Biosystems/Life
Technologies), and aligned using VectorNTi AlignX (Invitrogen/
Life Technologies).
Treatment of WM1552C cells with 5-aza-29-deoxycytidine
(5-Aza-dC)
WM1552C cells (5610
5) were plated into 75-cm
2 flasks. Each
flask was treated with 1, 2.5, 5, 7.5, or 10 mg/mL 5-Aza-dC or left
untreated. Each day for 5 days, the cells were washed once with
PBS, fed fresh medium, and treated as above. After day 5, the cells
were trypsinized, washed once with PBS, and centrifuged at
1200 rpm for 5 min. Cell pellets were prepared for total RNA
using the Trizol protocol (Invitrogen/Life Technologies), and
RNA was quantified using the ND-1000 spectrophotometer
(NanoDrop). The assay was performed in duplicate.
TaqMan Low Density Arrays
For cDNA synthesis and real-time PCR by Taqman Low
Density Array (TLDA), total RNA (800 ng) was subjected to 8
separate reverse transcription reactions (100 ng each) using
Multiplex RT for TaqManH MicroRNA Assays, Human Pool
Set kit (Applied Biosystems/Life Technologies). The resulting
cDNA (10 mL) was diluted 1:62.5 with nuclease-free water.
TLDAs consisting of a panel of 365 human miRNAs and 3
miRNA endogenous controls were run in triplicate for each
sample. Diluted cDNA (50 mL) was added to 50 mLo f2 6
TaqMan Universal Master Mix (No AmpErase UNG; Applied
Biosystems/Life Technologies). This 100 mL mixture was applied
to the respective array port and the TLDA was then centrifuged
twice and sealed. Quantitative real-time PCR was performed using
the Applied Biosystems 7900 Real-Time PCR Sequence Detection
System with the following thermal cycling parameters: 94.5uC for
30 s followed by 40 cycles of 97uC for 30 s, 59.7uC for 1 min.
Quantitative Real-time PCR
Total RNA was isolated by the Trizol method (Invitrogen/Life
Technologies) with subsequent quantification and integrity
analysis performed using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). Total RNA (100 ng) was
reverse transcribed using a High Capacity cDNA kit (Applied
Biosystems/Life Technologies), and quantitative reverse-transcrip-
tion PCR was carried out using TaqMan miRNA or mRNA
Assays or SYBR Green mRNA Assays and a 7500 Real-Time
PCR System (Applied Biosytems/Life Technologies) in accor-
dance with the manufacturer’s protocols. SYBR Green primers
include CDC42 (CDC42 qPCR For – ctgcacctacccacatgcactcgt
and CDC42 qPCR Rev - ttaactagtactgggagggggaaggg), FN1 (FN1
qPCR For – ggctgacagagaagattcccgagag and FN1 qPCR Rev -
ccagtttagatggatcttggcagagagac), and THBS2 (THBS2 qPCR For –
ttaccgcttcgtgcgctttgac and THBS2 qPCR Rev - aacagcgtgcccctg-
gacttg). SDS1.2.3 software (Applied Biosystems/Life Technolo-
gies) was used for comparative Ct analysis, with RNU48, GAPDH,
or b-actin serving as the endogenous controls.
Northern blot analysis
Total RNA concentrated from each sample (20 ng from cell
lines or 5-Aza-dC-treated melanoma cells as above), was analyzed
by northern blot. Samples were separated in 15% TBE-urea
polyacrylamide gels by electrophoresis and the RNA was
electroblotted onto nylon membranes, cross-linked by ultraviolet
light, prehybridized in Ultrahyb-Oligo (Ambion) for 30 min at
42uC, and hybridized with 59-biotinylated anti-miRNA DNA
oligonucleotides (100 nM each) at 42uC overnight. The blots were
then washed, and the signal was detected by chemiluminiscence
(Brightstar Detection kit, Ambion). Anti-U6 probes (10 pM) were
used as a reference control.
Construction of a melanoma cell lines stably expressing
miR-34b
Oligonucleotides complimentary to the hsa-miR-34b genomic
sequences were constructed (miR-34b pre For – gtgctcggtttgtagg-
cagtg and miR-34b pre Rev – gtgccttgttttgatggcagtg), containing
HindIII and BamHI sites on their respective 59 and 39 ends, then
amplified from melanocyte genomic DNA (Amplitaq Gold,
Applied Biosystems/Life Technologies). The product was then
TOPO cloned into pCR4-TOPO (Invitrogen/Life Technologies).
The vector construct was sequenced and the pre-hsa-miR-34b
fragment was sub-cloned into pcDNA4/myc-HisA (Invitrogen/
Life Technologies) using the HindIII and BamHI sites to create
pcDNA4/miR-34b. WM1552C and A375 melanoma cells
(2.5610
5) were seeded into single wells of a 6-well plate and
transfected with 5 mg pcDNA4/myc-HisA (Vector Control) or
pcDNA4/miR-34b using Fugene 6 (Roche). The following
morning, cells were selected with 600 mg/mL Zeocin for the
following 15 days. The remaining stable cells were then expanded
and named WM1552C/34b and WM1552C/VO (vector only) or
A375/34b and A375/VO (vector only).
Next-generation DNA sequencing and RNA-seq
Total RNA was isolated from samples using Trizol (Invitrogen/
Life Technologies) and fragmented through RNase III digestion.
SOLiD sequence protocols (Applied Biosytems/Life Technologies)
require reverse transcription of these RNAs, priming with a ligated
primer, and the resulting cDNA amplified and size-selected in a
6% urea gel with the help of SYBR Gold dye for sequencing. The
sequence libraries (150–200 bp size fragments) were further
amplified using a bead-based emulsion PCR optimized to
physically isolate a single bead/cDNA molecule. This enables
massively parallel amplification of monoclonal DNA species. For
RNA-seq experiments, we deposited approximately 90 million
beads per sample onto a glass slide and analyzed them using a
ligation-based sequencing technology. Data were mapped to the
human genome using both BioScope and BFAST software
packages and analyzed at the Burnham Institute Bioinformatics
core facility.
Methylated DNA enrichment and library construction
Genomic DNA (melanocytes, WM1552C and WM1552C +5-
Aza-dC) was fragmented to 50–400 bp (mean ,250 bp) using a
Covaris
TM S2 System (Woburn, MA), and 10 mg was subjected to
MBD-protein capture with the MethylMiner
TM Methylated DNA
Enrichment Kit (Life Technologies) following the recommended
protocol. The methylated DNA was resuspended in 40 mL
GibcoR UltraPure
TM DNase/RNase-Free Distilled Water (Life
Technologies) and quantified by UV absorbance spectroscopy. For
single-fraction elution, buffer containing 2 M NaCl was used to
elute methylated DNA captured using the MethylMiner
TM kit.
The methylated DNA fragments recovered were ethanol precip-
itated and resuspended. This DNA, and a sample of DNA that did
not undergo enrichment with the MethylMiner
TM kit (whole-
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TM System fragment
library construction, which includes a gel-based size selection step
to obtain a mean insert length of ,150 bp.
RNA-Seq gene analysis
Mapping of the SOLiD sequence data was performed using the
standard pipeline of Blat-like Fast Accurate Search Tool (BFAST)
[59] against the human genome (hg19) [60]. The BFAST
algorithm first creates indices of the human genome using different
masks (in this work, all 10 masks suggested in the BFAST manual
were used). It then hashes the reads to a number of genomic
locations based on the indices and performs detailed alignments
between the reads and the genomic sequence at the hashed
locations. The final output of BFAST contains the mapped
genomic locations of each read and the qualities (represented via
alignment scores) of the mappings.
The expression level of a gene can be calculated based on the
mapping results. The BFAST algorithm successfully mapped
,63% of the reads to the reference genome; among the mapped
reads, ,89% were uniquely mapped. Only uniquely mapped
reads were considered to eliminate possible noise. For each gene
(from the RefSeq annotation for hg19), a score was calculated as
reads per kilobase of sequence per million reads (RPKM) [61].
The predefined mapping protocol for SOLiD sequencing on
BioScope 1.0 was also used. BioScope was able to map ,63% of
the reads to the reference genome, ,83% uniquely. The output
was then fed into the Partek Genomics Suite for analysis. Again,
an RPKM score was computed for each gene.
The results of the two analysis pipelines were compared to
arrive at a consensus. Fold-change was computed for each gene,
this was a ratio of the WM1552C/34b RPKM over the
WM1552C/VO RPKM. For this calculation, a pseudo-count of
1.0 was used to overcome divide by zero errors and to normalize
the data at low RPKM values. A list of genes was produced such
that both programs agreed on the regulation direction (i.e. both
upregulated or downregulated). The order of the genes was then
directed by the corroborated fold change. For the open reading
frames, a cutoff was established with a minimum fold change of +/
21.5 (1.5 for miRNAs, 21.2 for target genes). The transcript delta
was also obtained; this was used to select genes for further testing,
this cutoff was set at 10.0 for open reading frames (1.3 for
miRNAs, 22.0 for target genes). The complete gene list is
available in the supplemental data.
Of particular interest are the target genes of miR-34b. This
target gene list was established from TargetScan 5.1 [62] utilizing
the top 500 miR-34b targets, irrespective of conservation. The
data acquired from deep sequencing was then filtered through the
target list to arrive at a final putative target list.
Cell adhesion assays
Trypsinized cells were counted, and 250,000 cells were seeded
per well into 12-well plates. At 5, 15, 30, 45, and 60 minutes after
seeding, floating cells were aspirated by rinsing the wells with PBS.
The remaining cells in the wells were trypsinized, resuspended in
cell media, and individually counted using the CountessH Cell
Counter (Invitrogen/Life technologies). Each sample was assayed
in triplicate at each time point, and each experiment was repeated
twice.
Invasion Assays
BD BioCoat
TM growth factor reduced insert plates (Matrigel
TM
Invasion Chamber 12 well plates) were prepared by rehydrating
the BD Matrigel
TM matrix coating in the inserts with 0.5 ml of
culture medium for 2 hrs at 37uC. The rehydration solution was
carefully removed from the inserts, 0.75 mL Complete Tu
medium containing chemoattractant (1% FBS) was added to the
lower wells of the plate, and 0.5 mL of cell suspension (1610
4 cells,
in serum-free medium) was added to each insert well. Invasion
assay plates were incubated for 48 hrs at 37uC. Following
incubation, the non-invading cells were removed by scrubbing
the upper surface of the insert. The cells on the lower surface of
the insert were stained with crystal violet and each trans-well
membrane mounted on a microscopic slide for visualization and
analysis. The slides were scanned using the Scanscope digital slide
scanner, and the number of cells migrating was counted using
Aperio software. Data are expressed as the percent invasion
through the membrane, relative to the migration through the
control membrane:
% invasion=Mean number of cells invading through the
Matrigel insert membrane/Mean number of WM1552C (wild-
type) cells migrating through membrane.
In vitro wound healing assay
WM1552C/34b and WM1552C/VO cells or A375/VO and
A375/34b cells were seeded on Mat Tek 1.5 mm tissue culture
dishes until 90–95% confluent. Cell monolayers were then gently
scratched with a pipette tip across the entire diameter of the dish
and extensively rinsed with medium to remove all cellular debris.
The surface area of the denuded surface was quantified
immediately after wounding and again every 20 minutes for
24 hrs on the Nikon Bio Station IM. The extent of wound closure
was determined by calculating the ratio of the surface area
between the remaining wound edges for each time point to the
surface area of the initial wound. These data were then expressed
as the percentage of wound closure relative to the control
conditions for each experiment. The surface area was calculated
using NIS Elements software and performed in triplicate.
Supporting Information
Figure S1 miR-34b expression in patient samples. miR-
34b expression was analyzed by qRT-PCR on patient samples, and
are expressed as RQ. Patient samples are annotated as follows:
(Nev)=nevi, (NS)=normal skin (P)=primary melanoma, (R)=re-
gional metastasis, (D)=distant metastasis, (N)=nodal metastasis.
(TIF)
Figure S2 miR-34b expression in WM1552C/34b (stable
ectopic expression), vector-only, cells treated with 5Aza-
dC, or untransfected parental cells subjected to Deep
Sequencing. RNA expression profiles for miR-34b were
measured in WM1552C melanoma cells which were stably
transfected with either an expression vector containing the mir-
34b gene (WM152C/34b), an empty vector (WM1552C/VO), no
vector (WM1552C or ‘‘wild type’’) or parental cells treated with 5-
Aza-dC.
(TIF)
Figure S3 Differential expression of mRNAs in miR-34b
expressing melanoma cells. RNA expression profiles were
measured in WM1552C melanoma cells stably transfected with
the mir-34b gene (WM152C/34b) or empty vector (WM1552C/
VO). A) Global expression profiling using both Bioscope and
BFAST revealed the three networks most perturbed in
WM1552C/34b cells compared to WM1552C/VO cells (using
GeneGo software). The expression ratios are transformed into
logarithmic scale. B) Filtering of next generation data revealed the
most up- or down-regulated coding genes in WM1552C/34b cells,
shown as log fold change versus WM1552C/VO cells. C) qRT-
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values are listed as RQ. Error bars are standard errors of mean.
(TIF)
Figure S4 Differential expression of miRNAs in miR-
34b-expressing melanoma cells. RNA expression profiles
were measured in WM1552C melanoma cells stably transfected
with the mir-34b gene (WM152C/34b) or with empty vector
WM1552C/VO). A) Filtering of next generation data revealed the
most up-regulated miRNAs in WM1552C/34b cells, listed as log
fold change versus WM1552C/VO cells. B) qRT-PCR validation
of the miRNA miR-140. Expression values are listed as RQ. Error
bars are standard errors of mean.
(TIF)
Table S1 Differential expression of mRNAs in miR-34b-
expressing melanoma cells. The results of next generation
data revealed the most up- or downregulated ORFs in
WM1552C/34b cells, listed by fold change and transcript
difference after consensus analysis by both Bioscope and BFAST
(as compared to WM1552C/VO cells).
(PDF)
Table S2 Differential expression of miRNAs in miR-34b
expressing melanoma cells. The results of next generation
data revealed the most upregulated miRNAs in WM1552C/34b
cells, listed by fold change and transcript difference after consensus
analysis by both Bioscope and BFAST (as compared to
WM1552C/VO cells).
(PDF)
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